Until the end of 2027, the EAEU countries, including Kazakhstan, will continue to register new drugs according to their usual rules - without switching to the unified requirements of the union. The decision on this was made by the Council of the Eurasian Economic Commission, the Ministry of Health of the Republic of Kazakhstan reports.
The decision also applies to changes in already registered drugs: they can be made in the same way as before.
"This is necessary to avoid drug shortages, supply disruptions and other risks for the healthcare system. Extending the deadlines will ensure a stable supply of all necessary drugs to the population," the Ministry of Health reported.
The decision comes into force on May 24 and will apply to legal relations that arose from January 1, 2025.
Источник: Казахстанский Фармацевтический Вестник, pharmnews.kz
The decision also applies to changes in already registered drugs: they can be made in the same way as before.
"This is necessary to avoid drug shortages, supply disruptions and other risks for the healthcare system. Extending the deadlines will ensure a stable supply of all necessary drugs to the population," the Ministry of Health reported.
The decision comes into force on May 24 and will apply to legal relations that arose from January 1, 2025.
Источник: Казахстанский Фармацевтический Вестник, pharmnews.kz
